In MM, preclinical data shows that lenalidomide, one of the so-called immunomodulatory drugs (IMiDs), reduce the expression of PD-1 and PD-L1 in MM cells and BM accessory cells isolated from RRMM patients. Here, CD274 is linked to Miyoshi myopathy.